Komori
Kissei Pharmaceutical (4547) · InitiativeAdvanced

Preparation for TCFD Disclosure on Climate Change Risks

First written in FY2022. 2 of 4 entries say "Advanced", first in FY2024. Latest entry: FY2026.

4entries
5years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2022AdvancedFY2024ReframedFY20252022: 120222023: 020232024: 120242025: 120252026: 12026
Same theme, other companies
TCFD-Based Climate Change Scenario Analysis and DisclosureA theme 559 companies write about · 115 as a headwind · 329 as a tailwind
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 195 companies compared. The sentences above are computed from all 195.Comparing 200 of the theme's 575 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「The Group's CO2 emissions in FY2025 were 10,737 tonnes (Scope 1: 10,196 tonnes; Scope 2: 541 tonnes), a 39% reduction from FY2020. For Scope 2, the Group has progressively introduced renewable energy since FY2022. In FY2025, renewable energy accounted for approximately 83% of the Group's total electricity consumption, reducing annual CO2 emissions by 7,244 tonnes from FY2020.」

    The Company updated its FY2025 CO2 emissions, reduction rate from the base year and renewable energy usage rate against the targets of a 42% reduction by FY2030 and net zero by FY2050. It also made its TCFD-based 1.5°C and 4°C scenario analyses and response measures more specific.
  2. FY2025ReframedAnnual report

    「2050 CO2 emissions target (Scope 1 + 2): net zero ・2030 CO2 emissions target (Scope 1 + 2): 42% reduction from FY2020 The Group's CO2 emissions in FY2024 were 11,098 tonnes (Scope 1: 10,386 tonnes; Scope 2: 712 tonnes), a 37% reduction from FY2020. … In FY2024, renewable energy accounted for approximately 80% of the Group's total electricity consumption.」

    The baseline for the target was changed from FY2013 to FY2020, and a net-zero target for FY2050 was established. In FY2024, CO2 emissions were reduced by 37% from the base year, and the renewable energy usage rate reached approximately 80%.
  3. FY2024AdvancedAnnual report

    「2030 CO2 emissions target (Scope 1 + 2): 46% reduction from FY2013 ・2030 renewable energy usage target: at least 74% of total electricity consumption As a result of introducing renewable energy progressively from FY2022, the renewable energy usage rate was approximately 77% in FY2023, achieving the FY2030 target of 74% ahead of schedule. CO2 emissions decreased by approximately 7,200 tonnes annually from FY2013.」

    The Company conducted TCFD 1.5°C and 4°C scenario analyses and set FY2030 targets. The renewable energy usage rate reached approximately 77%, achieving the 74% target ahead of schedule.
  4. FY2022First statedAnnual report

    「With regard to climate change risks related to environmental conservation, the Company is preparing to disclose information in response to the recommendations of the Task Force on Climate-related Financial Disclosures (TCFD).」

    The Company explicitly disclosed for the first time its preparations for information disclosure based on the TCFD recommendations regarding climate change risks.
Moved together

"Enhancing and Strengthening a Product Portfolio with Distinctive Features and Competitive Advantages" moved the same way as this thread, in the same document, in 2 of its 4 moves.

222222★123456
  1. ★This thread
  2. 1Enhancing and Strengthening a Product Portfolio with Distinctive Features and Competitive Advantages2×
  3. 2Efficient Advancement of Clinical Trials for Development Programs and Early Approval2×
  4. 3Establishing a Competitive Advantage and Securing Sales in the Domestic Prescription Pharmaceutical Market2×
  5. 4Promoting overseas expansion and stabilizing the overseas earnings base2×
  6. 5Securing Profitability and Expanding the Healthcare Business2×
  7. 6Building an Efficient Production System and Ensuring a Stable Supply of High-Quality Pharmaceuticals2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Kissei Pharmaceutical's next results are scheduled for 2026-11-04. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Preparation for TCFD Disclosure on Climate Change Risks | KISSEI PHARMACEUTICAL CO.,LTD. (4547) | Komori